NEW YORK – Personalis said today that it is engaged in a research collaboration with Sarepta Therapeutics in which it is using its platform to characterize the immune response to certain precision genetic therapeutics.
Financial terms of the deal were not disclosed and Personalis did not name specific drugs or disease areas being studied, but Sarepta describes its pipeline as encompassing a suite of experimental genetic medicines for to treat rare neuromuscular and central nervous system diseases.
Tanya Teslovich, senior director of genomics at Sarepta also suggested that the project involves neoepitope prediction.
Personalis CSO Richard Chen said in a statement that the partnership helps demonstrate the extensibility of the company's technology platform beyond cancer. The firm recently launched a dedicated pharma services program, aiming to attract a wider range of customer research goals and disease areas than the clinical cancer research that had been its mainstay.